![Xiaogang Pan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Xiaogang Pan currently works at CICC Capital Operation Co. Ltd., as Managing Director from 2015, Cullgen, Inc., as Director, and Rgenta Therapeutics, Inc., as Director.
| Sociétés | Poste | Début |
|---|---|---|
Cullgen, Inc.
 Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that focused on discovery and development of targeted protein degrader and DAC therapies for cancer and inflammatory & pain diseases | Directeur/Membre du Conseil | - |
Rgenta Therapeutics, Inc.
 Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pipeline of oral and small-molecule RNA-targeting medicines | Directeur/Membre du Conseil | - |
CICC Capital Operation Co. Ltd.
 CICC Capital Operation Co. Ltd. Investment ManagersFinance Functions as an alternative investment manager | Private Equity Investor | 01/01/2015 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 3 |
|---|---|
Cullgen, Inc.
Cullgen, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that focused on discovery and development of targeted protein degrader and DAC therapies for cancer and inflammatory & pain diseases | Health Technology |
Rgenta Therapeutics, Inc.
Rgenta Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops pipeline of oral and small-molecule RNA-targeting medicines | Health Technology |
CICC Capital Operation Co. Ltd.
CICC Capital Operation Co. Ltd. Investment ManagersFinance Functions as an alternative investment manager | Finance |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
